Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Liposarcoma × Sugars × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 cyclopia sequence 7 Neoplasms 6 Prostatic Neoplasms 5 Lung Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Polycystic Ovary Syndrome 3 Pain 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Fatigue 3 Vomiting 2 Urinary Bladder Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Obesity 2 Neoplasms, Plasma Cell 2 Nausea 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Leiomyoma 2 Hematologic Diseases 2 Head and Neck Neoplasms 2 Burkitt Lymphoma 2 Weight Loss 1 Warts 1 Vitamin D Deficiency 1 Tobacco Use Cessation 1 Testicular Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1

Interventions

Doxorubicin 20 Trabectedin 10 Radiotherapy 10 Ifosfamide 10 pazopanib 5 Gemcitabine 5 ribociclib 4 Specimen Handling 4 Docetaxel 4 Biopsy 4 selinexor 3 pembrolizumab 3 palbociclib 3 eribulin 3 X-Rays 3 Filgrastim 3 Cyclophosphamide 3 temsirolimus 2 pegfilgrastim 2 liposomal doxorubicin 2 cixutumumab 2 brostallicin 2 brigimadlin 2 belinostat 2 avelumab 2 abemaciclib 2 Vincristine 2 Temozolomide 2 Surgical Procedures, Operative 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡